Tigecycline for the treatment of patients with severe sepsis or septic shock: A drug use evaluation in a surgical intensive care unit

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 729-733

  Swoboda, Stefanie ^a   Ober, Michael ^a   Hainer, Christian ^a   Lichtenstern, Christoph ^a   Seiler, Christoph ^a   Wendt, Constanze ^b   Hoppe tichy, Torsten ^a   Büchler, Markus ^a   Weigand, Markus A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibiotic usage; Intra abdominal infections; Methicillin resistant Staphylococcus aureus; Vancomycin resistant enterococci

Indexed keywords

AMIKACIN; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; COLISTIN; METICILLIN; QUINOLONE; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMORBIDITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

AGED; DRUG EVALUATION; FEMALE; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 40049106190     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm541     Document Type: Article

References (25)

1. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34 344-53.
2. Angus DC, Wax RS. Epidemiology of sepsis: An update. Crit Care Med 2001; 29 Suppl 7: S109-16.
3. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
4. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-713.
5. Tygacil® Product Information. Taplow, Maidenhead, UK: Wyeth Europa Ltd, 2006.
6. Tygacil® Prescribing Information. Philadelphia, PA, USA: Wyeth Pharmaceuticals Inc., 2007.
7. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
8. Zhanel GG, Karlowsky JA, Rubinstein E et al. Tigecycline: A novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006; 4 9-25.
9. Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65: 2623-35.
10. Noskin GA. Tigecycline: A new glycylcycline for treatment of serious infections, Clin Infect Dis 2005; 41 Suppl 5: S303-14.
11. Breedt J, Teras J, Gardovskis J et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
12. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of. tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
13. Sader HS, Jones RN, Dowzicky MJ et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
14. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
15. Levy MM, Fink MF, Marshall JO et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
16. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A6. NCCLS, Wayne, PA, USA; 1997.
17. Bodmann K-F, Vogel F. Antimikrobielle Therapie der Sepsis. Empfehlungen der Arbeitsgruppe, der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Chemotherapie J 2001; 2: 43-56.
18. Vogel F, Bodmann K-F, and Expertenkommission der Paul-Ehrlich-Gesellschaft for Chemotherapie e.V. Empfehlungen zur kalkulierten parenteralen. Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Arzneimitteltherapie 2004; 9: 271-81.
19. Solomkin JS, Mauski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 37: 997-1005.
20. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-18.
21. Paterson DL. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4: S341-5.
22. Robert Koch-Institut. Zur MRSA-Situation in Deutschland im Jahr 2003. Bericht aus dem Nationalen Referenzzentrum für Staphylokokken. Epidemiologisches Bull 2004; 42: 303-66.
23. Petersdorf S, Oberdorfer K, Wendt C. Longitudinal study of the molecular epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. J Clin Microbiol 2006; 44: 4297-302.
24. Swoboda S, Hoppe-Tichy T, Geiss HK et al. [Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy]. Anaesthesist 2007; 56: 169-74.
25. Taccone FS, Rodriguez-Villalobos H, De Backer D et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.